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ABSTRACT 
To  evaluate  the  food  effect  on  pharmacokinetic 
parameters  of  losartan  and  its  active  metabolite 
pharmacokinetics  data  of  reference  product  100mg 
tablet of two bio-equivalence studies  were combined 
and  analyzed.  Fifty  two  and  fifty  nine  healthy  male 
subjects  participated  respectively  in  fasting  and  non-
fasting study. Subjects received 100mg losartan tablet 
after overnight fasting condition of 12 hours for fasting 
study and after 30 minutes of high fat breakfast for non 
fasting  study.  Blood  samples  were  collected  prior  to 
dosing and at regular time intervals as per predefine 
sampling time point over a period of 48 hours. Plasma 
samples  were  analysed  for  concentration  of  losartan 
and  its  metabolite  using  validated  liquid 
chromatograph  mass  spectroscopy  (LC-MS/MS) 
technique. The maximum plasma concentration (Cmax) 
of  losartan  and  its  metabolite  were  decreased  up  to 
16%  and  17%  respectively.  The  area  under  curve 
(AUC) increased about 14% for losartan and decreased 
about  4%  for  metabolite  whereas  Time  to  attain 
maximum concentration (Tmax) were delayed about 107 
% (from 1.36 h to 2.82 h) and 59 % (from 3.058 to 
4.864 hours) for losartan and metabolite respectively. 
Elimination constant (Kel) for losartan was delay 18 % 
for fasting study and for metabolite Kel was delay 4 % 
for  fasting  study.  For  the  log  transformed  data  of 
losartan, food effect  was found for pharmacokinetics 
parameters  Cmax,  AUCt  (area  under  curve  up  to  last 
measurable time point) and AUCi (area under curve up 
to  infinity  time).  While  in  case  of  metabolite  food 
effect  was  found  for  Cmax  lack  of  food  effect  was 
observed  on  AUCt  and  AUCi  of  clinically  active 
metabolite which conformed food had not a significant 
effect on the efficacy of the losartan.    
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INTRODUCTION 
Losartan is an Angiotensin II receptor blocker having 
antihypertensive activity.
1 It is orally active synthetic 
agent,  chemically  know  as  2-butyl-4-chloro-1-[p-(o-
1Htetrazol-5-ylphenyl)  benzyl]  imidazole-5-methanol 
monopotassium  salt.
2  Losartan  is  a  nonpeptide 
angiotensin  II  receptor  blocker
3  Losartan  have  33% 
oral bioavailability after rapid absorption and a short 
half-life. It is converted to more potent clinically active 
carboxylic acid metabolite (E3174) having longer half-
life  by  cytochrome  P450  systerm
4  Losartan  first 
converted to E3179 intermediate metabolite which is 
converted  to  active  metabolite  E3174  through 
cytochrome  (CYP)  P450.
5  Isoenzyme  CYP2C9  is 
prime responsible for metabolism of losartan. Losartan 
is  also  metabolised  by  an  isoenzyme  CYP3A4  and 
CYP2C10.
6  For  the  oral  administration,  maximum 
plasma concentration of losartan and active metabolite 
reached  after  1  hour  and  3  to  4  hours  respectively. 
Losartan  and  active  metabolite  have  approximately 
equal maximum plasma concentration while area under 
curve of metabolite is fourfold higher than losartan. On 
oral administration 4.2% and 6.1% of losartan and it’s 
active metabolite (E3174) were excreted in urine.
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MATERIALS AND METHODS 
Study population 
Volunteers  (subjects)  for  two  independent  bio-
equivalence  study  were  included  as  per  the  criteria 
mentioned in protocol which include age (18years or 
above),  body  mass  index  (between  18.5  and 
30.0kg/height
2)  [Table-1],  general  physical 
examination,  electrocardiogram  and  laboratory  tests 
like  hematology,  blood  chemistry,  urine  examination 
and  immunological  tests.  The  exclusion  criteria 
included history of alcoholism, smokers and having a 
disease  which  may  compromise  the  haemopoietic, 
gastrointestinal,  renal,  hepatic,  cardiovascular, 
respiratory, central nervous system, diabetes, psychosis 
or  any  other  body  system.  All  the  subjects  met 
inclusion and exclusion criteria mentioned in protocol 
and  were  judged  eligible  for  study,  based  on 
medication  history,  physical  examination,  vital  signs 
and  clinical  laboratory  tests.  Approval  for  the  study 
was obtained from Independent Ethics Committee.  
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The  study  was  conducted  in  accordance  with 
internationally  accepted  standards  of  Good  Clinical 
Practices (ICH), Good Laboratory Practices (21 CFR 
51 and local regulatory requirements)
8  
 
Table- 1: Demographics table  
Study design and treatments 
Both  the  bio-equivalence  studies  were  Single  dose, 
open  label,  two  sequence,  two  period,  randomized, 
balanced, crossover studies conducted with 52 and 59 
healthy,  adult,  male  human  subjects  for  fasting  and 
non-fasting  phase  respectively.  In  the  fasting  study 
Losartan 100 mg tablet (COZAAR
® of Merck & Co, 
Whitehouse station, NJ 08889, USA) was administered 
after  overnight  fasting  of  12.0  hour,  subjects  were 
served food at different timings  which contained the 
nutrients.[Table-4]. In the non- fasting study Losartan 
100  mg  tablet  (COZAAR
®  of  Merck  &  Co, 
Whitehouse station, NJ 08889, USA) was administered 
after 30 minutes of high fat breakfast, subjects  were 
served  food  at  different  time  which  contained  the 
nutrients. 
Blood sampling  
Blood  samples  were  collected  in  vacutainers 
containing K3 EDTA prior to dosing and at predefine 
sampling time points as follows, 0.25, 0.5, 0.75, 1.0,  
1.5,  2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 
12.0, 16.0, 24.0, 36.0 and 48.0 hours post dose. Blood 
samples  were  centrifuged  at  4C  for  15  min.  and 
plasma  was  separated,  transferred  to  labelled 
polypropylene tubes and stored in the freezer set at -
20C ±10C until analysis. 
 
Bioanalytical Method  
Plasma  concentrations  of  losartan  and  its  metabolite 
were  estimated  by  a  validated  LC-MS/MS  method. 
Losartan and its metabolite were extracted from plasma 
samples  by  using  protein  precipitate  method. 
Verapamil was used as an internal standard. The range 
of the linear dynamic calibration curves was kept from 
2.000ng/mL  to  1500ng/mL  for  drug  and  metabolite 
both  and  API  3000  tandem  mass  spectrometer  was 
used for analysis.  
PHARMACOKINETICS ANALYSIS 
The  pharmacokinetic  parameters  of  losartan  and  its 
active  metabolite  were  estimated  using  non-
compartmental  analysis  with  WinNonlin-Professional 
software and statistical analysis was performed on log 
transformed  data  obtained  from  the  same.  The 
pharmacokinetic parameters estimated were Cmax, Tmax, 
AUCt (the area under the plasma concentration –time 
curve from time zero to the time of the last non zero 
concentration)  and  AUCi  (the  area  under  the  plasma 
concentration  –time  curve  from  time  zero  to  the 
infinite time).  
RESULTS 
All oral doses were well tolerated by the subjects, and 
no adverse events were reported.  
Losartan: Food intake increased AUC of losartan by 
about 14% while decreased Cmax of losartan by about 
16%. Tmax was delayed by about 107% (1.36 hr to 2.82 
hr) and Kel was delayed by about 18% (0.337 hour to 
0.400  hour)  which  indicates  food  intake  delays  the 
absorption  of  losartan.  Statistical  results  on  log-
transformed data, 90% confidence intervals (CI 90%) 
and  P-value  are  given  in  Table-3  &  4.  Mean 
Concentration-Time  profile  of  Losartan  is  shown  in 
Fig. 1. 
 
Metabolite: Food intake decreased AUC of metabolite 
by  about  4%,  Cmax    by  about  17%,  delayed  Tmax  by 
about 59% (3.058 hour to 4.864 hour) and delayed Kel 
by about 4%. Statistical result on log-transformed data, 
CI 90% and P-value are given in Table-2 & 3. Mean 
Concentration-Time profile of Metabolite is shown in 
Fig.1.  
  Non fasting 
study 
Fasting 
study 
Subjects enrolled  60  52 
Study completed   59  52 
Gender   Males   Males 
Age 
(Years) 
Mean(±SD)  25.3(±5.1)  24.3(±4.8) 
Median  24.0  23.0 
Min  18.0  19.0 
Max  39.0  39.0 
Weight 
(kg) 
Mean(±SD)  57.1(±6.9)  57.7 
(±6.7) 
Median  55.0  56.0 
Min  46.0  45.5 
Max  73.0  77.8 
 
Height 
(cm)  
Mean(±SD)  167.5(±5.6)  167.1(±4.
6) 
Median  168.0  166.5 
Min  152.0  156.0 
Max  180.0  177.0 
Race  Asian  Asian  
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Fig.1 Mean Concentration-Time profile of Losartan 
& Metabolite 
 
 
 
 
 
 
 
 
Table-2: Statistical result of pharmacokinetics 
parameters of Losartan and Metabolite  
 
n: Number of subjects enrolled 
AUCt: Area under the plasma concentration-time curve from zero 
hour to 48 hour 
Cmax: Maximum plasma concentration 
Tmax: Time point of maximum plasma concentration 
 
 
 
 
 
 
 
 
 
 
 
Table-4: Nutrition during study 
 
Timing  Carbohydrates 
(gm) 
Proteins (gm)  Fat (gm)  Energy (K.Cal.) 
Fasting  Non 
fasting 
Fasting  Non 
fasting 
Fasting  Non fasting  Fasting  Non 
fasting 
Breakfast  NA  61.60  NA  42.60  NA  66.35  NA  1013 
Lunch  141.9  141.9  30.30  30.30  23.10  23.10  890.0  890.0 
Snacks  93.20  55.60  6.250  4.300  14.00  11.30  523.0  323.0 
Dinner  150.0  148.2  32.60  21.70  23.50  18.20  923.0  840.0 
Breakfast  57.75  57.75  14.25  14.25  6.50  6.500  345.0  345.0 
Total  442.9  465.1  83.40  113.2  67.10  125.5  2681  3411 
NA=Not Applicable 
Table-3: Statistical result of pharmacokinetics parameters of Losartan and Metabolite  
 
Dependent  (fed/fasting) Ratio (%)  CI  90 Lower  CI 90 Upper  P-value 
Losartan  Metabolite  Losartan  Metabolite  Losartan  Metabolite  Losartan  Metabolite 
Ln Cmax  88.28  82.90  76.11  69.26  102.4  99.28  0.1661  0.0872 
Ln AUCt  117.4  96.45  105.5  83.18  130.7  111.8  0.0144  0.6862 
Ln AUCi  117.5  96.64  105.6  83.57  130.7  111.7  0.0137  0.6967 
Statistical results of pharmacokinetics parameters 
Parameters  Losartan  Metabolite 
Fasting 
(n=52) 
Non 
fasting 
(n=59) 
Fasting 
(n=52) 
Non 
fasting 
(n=59) 
AUC  Mean  874.3  1004  5277  5065 
Std. 
Deviation 
339.0  313.0  1950  1607 
Cmax  Mean  534.6  448.2  900.3  747.5 
Std. 
Deviation 
287.1  175.5  364.1  271.2 
Tmax  Mean  1.356  2.820  3.058  5.000 
Std. 
Deviation 
0.6570  1.467  0.9380  1.456  
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CONCLUSION  
Determination  of  losartan  and  metabolite  has  been 
performed  by  using  high-performance  liquid 
chromatography  (HPLC)-electrospray  ionization 
tandem  mass  spectrometry  (MS-MS).  Use  of  a 
sensitive and specific LC/MS/MS method in this study 
allowed  a  better  characterization  of  the 
pharmacokinetic profile of losartan and its metabolite. 
Food  may  affect  the  pharmacokinetics  of  drugs  by 
different  ways,  including  delayed  gastric  emptying, 
solubilisation  of  drug  by  food  and  digestive  fluids, 
complexation of drug with food components, alteration 
in  hepatic  blood  flow  and  modulation  of  drug 
metabolizing enzymes by constituents of food.
[9]      
    
In addition, food intake has been found to influence the 
bioavailability  of  drugs  with  extensive  presystemic 
metabolic clearance.
[10] Cytochromes P450 are a group 
of  heme-thiolate  monooxygenases.  In  liver 
microsomes, this enzyme is involved in an NADPH-
dependent  electron  transport  pathway.  It  oxidizes  a 
variety of structurally unrealted compounds, including 
steroids,  fatty  acids,  and  xenobiotics.  This  enzyme 
contributes to the wide pharmacokinetics variability of 
the  metabolism  of  drugs  such  as  S-  warfarin, 
diclofenac,  phenytoin,  tolbutamide  and  losartan. 
Cytochrome  P4502C9  and  3A4  are  involved  in  the 
biotransformation of losartan to its metabolites.
[11] In 
present  work  food  intake  increased  AUC  of  losartan 
while as Cmax of losartan decreased, delayed Tmax and 
Kel indicates food intake delay absorption of losartan. 
For  the  losartan  90%  confidence  intervals  of  Cmax, 
AUCt and AUCi not within limit (80% to 125%) and 
fed to fasting geometric mean ratio of AUCt and AUCi 
not  within  limit  (80%  to  125%).  Hence,  food  effect 
was  found  for  pharmacokinetics  parameters  Cmax, 
AUCt and AUCi of losartan. In case of metabolite Cmax 
and AUC were decreases due to food intake. For the 
metabolite 90% confidence intervals of Cmax not within 
limit  (80%  to  125%)  while  AUCt  and  AUCi  within 
limit (80% to 125%) and fed to fasting geometric mean 
ratio  of  Cmax,  AUCt  and  AUCi  within  limit  (80%  to 
125%)  indicates  food  effect  was  found  for 
pharmacokinetics  parameter  Cmax  of  metabolite.  The 
efficacy  of  any  drug  widely  effected  by  variation  in 
AUC,  in  present  study  AUC  of  clinically  active 
metabolite have no food effect which indicates efficacy 
of losartan not effected by presence of food.   
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